ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES

/in

Link to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]

Read more

Cynata Secures $15m Placement Led By $10M from Healthcare Investor BioScience Managers to Expand Development Pipeline

/in

Melbourne, Australia; 11 December 2020: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement (“Placement”), led a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate […]

Read more

Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors

/in

Link to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected the Armata shareholders […]

Read more

BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award

/in

Melbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]

Read more

GEN INCODE APPOINTS CHIEF FINANCIAL OFFICER

/in

Link to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]

Read more

AVITA Therapeutics Powers BioScience Managers to Prestigious Australian Investment Council Award

/in

Melbourne, Australia 7 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd has received the 2020 Best Venture Capital Investment Award at the prestigious Australian Investment Council Investing for Growth Awards 2020.   The Best Venture Capital Investment Award recognises BioScience Managers’ patient eight-year investment in AVITA Therapeutics, Inc., a regenerative medicine company that […]

Read more

Destiny Pharma – Result of General Meeting and Total Voting Rights

/in

Link to Full Article Destiny Pharma plc  (“Destiny” or the “Company”) Result of General Meeting  and Total Voting Rights  Brighton, United Kingdom ‐ 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier […]

Read more

Destiny Pharma announces total gross proceeds raised via Open Offer

/in

Link to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of Open Offer Brighton, United Kingdom ‐ 25 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that it has conditionally raised total gross proceeds of approximately £0.87m […]

Read more

Minister for Industry, Science and Technology $41.7 million boost to commercialise lifesaving medical discoveries

/in

Link to Full Article Joint media release with Minister for Industry, Science and Technology, Karen Andrews, announcing $500 million to take an innovative nasal treatment to fight COVID-19, common colds and flu to the next stage of testing. An innovative nasal treatment to fight COVID-19, common colds and flu is being taken to the next […]

Read more

Congenica Completes $50m Series C Funding Round to Advance Clinical Genomic Analysis Software and Data Platform

/in

Link to Full Article New Funds to Drive Further Commercialisation of Rare and Inherited Cancer Applications and Expansion into Oncology, Wellness and Pharma Collaborations Cambridge, United Kingdom – 9 November 2020 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the completion of […]

Read more